Satraplatin

Satraplatin is an orally available antineoplastic platinum(IV) complex. It is more hydrophobic than cisplatin (Cay-13119) or oxaliplatin (Cay-13106), which reduces transport-determined acquired resistance. Satraplatin also displays less neurotoxicity in rats than cisplatin or tetraplatin. Satraplatin has a favorable toxicity profile and appears to have clinical activity against a variety of malignancies.Formal Name: (OC-6-43)-bis(acetato-kappaO)amminedichloro(cyclohexanamine)-platinum. CAS Number: 129580-63-8. Synonyms: BMS-182751, BMY 45594, JM 216. Molecular Formula: C10H22Cl2N2O4Pt. Formula Weight: 500.3. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 0.16 mg/mL, DMSO: 0.5 mg/mL. lambdamax: 211 nm. SMILES: [Cl-][Pt+4]([O-]C(C)=O)([O-]C(C)=O)([Cl-])([NH3])[NH2]C1CCCCC1. InChi Code: InChI=1S/C6H13N.2C2H4O2.2ClH.H3N.Pt/c7-6-4-2-1-3-5-6,2*1-2(3)4,,,,/h6H,1-5,7H2,2*1H3,(H,3,4),2*1H,1H3,/q,,,,,,+4/p-4. InChi Key: CKNPWBAXEKSCRG-UHFFFAOYSA-J.